Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism

Warfarin and direct oral anticoagulant agents prevent recurrent venous thromboembolism. When a first episode of venous thromboembolism occurs in association with a transient risk factor (e.g., surgery), treatment can be stopped after 3 months. With persistent and strong risk factors, such as cancer, therapy should be continued indefinitely.1 Prolonged anticoagulation therapy is now suggested for most patients with unprovoked venous thromboembolism. Cessation of therapy after 3 to 6 months may be recommended in some female patients who are judged to be at low risk for recurrence,2 in patients at high risk for bleeding, and in patients with poor adherence or . . .